Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-Year prospective study

Table 2 Baseline predictors and 5-year outcomes

	VR %	P-value	HBeAg loss %	P-value	HBeAg seroconversion %	P-value
ALT≥5 × ULN	75.0%	0.035	43.9%	0.017	37.9%	0.035
ALT < 5 × ULN	43.8%		13.8%		13.8%
HBeAg < 800 s/co	88.9%	0.027	77.8%	0.045	27.8%	0.831
HBeAg≥800 s/co	47.6%		38.0%		19.0%
HBsAg < 5000 IU/ml	80.0%	0.132	80.0%	0.026	27.8%	0.200
HBsAg≥ 5000 IU/ml	59.3%		48.1%		24.1%
HBV DNA < 9 log₁₀ copies/ml	71.9%	0.494	61.8%	0.621	26.5%	0.702
HBV DNA≥ 9 log₁₀copies/ml	69.2%		53.9%		15.4%

ISSN: 1743-422X